Transfusion burden reduction vs baseline for patients with β-thalassemia treated with luspatercept (n = 32). (A) Percentage change in RBC transfusion burden over a continuous 12-week period post baseline vs the 12-week baseline period. Each bar represents 1 patient; the best recorded continuous 12-week period of transfusion burden reduction post baseline was used to calculate the percentage change for each patient. (B) Absolute change in RBC units on study vs baseline. Each circle represents 1 patient’s baseline RBC transfusion burden, as absolute number of transfused units in a 12-week period; each line represents the best recorded transfusion burden reduction for the patient over a continuous 12-week period post baseline. For both panels, only patients with a baseline transfusion burden of ≥2 RBC units and 12-week postbaseline transfusion data are shown.